AQR Capital Management’s Harvard Bioscience HBIO Stock Holding History

AQR Capital Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,571	Closed	-$20.3K	–	3515
2025 Q2	$20.3K	Buy	4,571 +2,293	+101%	+$9.58K	﹤0.01%	3283
2025 Q1	$12.9K	Buy	+2,278	New	+$29.2K	﹤0.01%	3139
2023 Q4	–	Sell	-1,176	Closed	-$50.5K	–	2378
2023 Q3	$50.5K	Buy	+1,176	New	+$54.3K	﹤0.01%	2283
2022 Q3	–	Sell	-3,436	Closed	-$124K	–	2250
2022 Q2	$124K	Sell	3,436 -19,025	-85%	-$859K	﹤0.01%	2062
2022 Q1	$1.4M	Sell	22,461 -13,263	-37%	-$785K	﹤0.01%	1373
2021 Q4	$2.52M	Buy	35,724 +4,389	+14%	+$312K	﹤0.01%	1049
2021 Q3	$2.19M	Buy	31,335 +28,876	+1,174%	+$2.3M	﹤0.01%	1087
2021 Q2	$205K	Buy	+2,459	New	+$174K	﹤0.01%	2137

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

AQR Capital Management's HBIO Position: Q3 2025 in Review

AQR Capital Management sold out of Harvard Bioscience (HBIO) in Q3 2025, closing a stake of 4,571 shares — an estimated $20.3K sold.

AQR Capital Management first reported a position in HBIO in Q2 2021 and held it in 8 quarters. The position peaked at $2.52M in Q4 2021. 59 funds tracked by Wall St. Rank hold HBIO as of Q3 2025.

AQR Capital Management reported no remaining Harvard Bioscience position as of Q3 2025 after selling out during the quarter.
AQR Capital Management sold 4,571 Harvard Bioscience shares in Q3 2025, an estimated $20.3K.
AQR Capital Management first reported a position in Harvard Bioscience in Q2 2021 and held it in 8 quarters.
AQR Capital Management's Harvard Bioscience position peaked at $2.52M in Q4 2021.
59 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.